Yahoo Finance

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

LANGHORNE, Pa., December 02, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European ...
FierceBiotech

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients.
Business Insider

PARI Pharma development featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) is licensed to Breath Therapeutics

STARNBERG, Germany, March 20, 2017 /PRNewswire/ -- PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for ...
Business Insider

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...
Business Wire

Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) ...
Seeking Alpha

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological ...